UNLIMITED TURBO SHORT - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 01:20:29 01/06/2024 am IST | ||
| 4.47 EUR | -0.67% |
|
| 1 month | +0.68% | ||
| 3 months | +18.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 4.47 | -0.67% |
| 30/24/30 | 4.5 | -0.88% |
| 29/24/29 | 4.54 | +1.11% |
| 28/24/28 | 4.49 | +3.46% |
| 27/24/27 | 4.34 | -0.23% |
Delayed Quote Deutsche Boerse AG
Last update May 01, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE5169 |
| ISIN | DE000PE51695 |
| Date issued | 28/11/2022 |
| Strike | 112.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.96 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.67 € |
|---|---|
| Lowest since issue | 2.32 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.27
USD
Average target price
82.7
USD
Spread / Average Target
+28.67%
- Stock Market
- Certificates
- Certificat
